PH24180A
(en)
|
1986-03-12 |
1990-03-22 |
Glaxo Group Ltd |
Macrolide compounds,pharmaceutical composition containing said compound and method of use thereof
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
ES2113879T3
(es)
|
1990-01-24 |
1998-05-16 |
Douglas I Buckley |
Analogos de glp-1 utiles para el tratamiento de diabetes.
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
KR960701653A
(ko)
|
1993-03-29 |
1996-03-28 |
발라수브라마니암 엠비카이파칸 |
펩타이드 yy의 유사체 및 그의 용도
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
WO1995033474A1
(fr)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Composition medicinale
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
BR9604880A
(pt)
|
1995-03-31 |
1998-05-19 |
Emisphere Tech Inc |
Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
RU2214419C2
(ru)
|
1996-08-30 |
2003-10-20 |
Ново Нордиск А/С |
Glp-1 производные
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
ATE366584T1
(de)
|
1996-11-12 |
2007-08-15 |
Novo Nordisk As |
Verwendung von glp-1 peptiden
|
AU1159897A
(en)
|
1996-11-13 |
1998-06-03 |
University Of Cincinnati, The |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
WO1999043706A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
DE69942307D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
AU2610799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
AU4317899A
(en)
|
1998-06-08 |
1999-12-30 |
Schering Corporation |
Neuropeptide y5 receptor antagonists
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
EP1100530B1
(en)
|
1998-07-31 |
2003-10-08 |
Novo Nordisk A/S |
In-vitro stimulation of beta cell proliferation
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
PL202367B1
(pl)
|
1998-12-07 |
2009-06-30 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
|
EP1149066B1
(en)
|
1999-02-05 |
2005-11-09 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
CA2363123C
(en)
|
1999-02-22 |
2011-09-06 |
Kenneth Iain Cumming |
Solid oral dosage form containing an enhancer
|
WO2000048589A1
(en)
|
1999-02-22 |
2000-08-24 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
PT1180121E
(pt)
|
1999-05-17 |
2004-03-31 |
Conjuchem Inc |
Peptidos insulinotropicos de longa duracao
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
KR20080085082A
(ko)
|
2000-12-07 |
2008-09-22 |
일라이 릴리 앤드 캄파니 |
Glp-1 융합 단백질
|
AU2002228608A1
(en)
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
RU2275207C2
(ru)
|
2000-12-14 |
2006-04-27 |
Амилин Фармасьютикалз, Инк. |
Способ снижения доступности питательного вещества, способ подавления аппетита
|
GB0102075D0
(en)
*
|
2001-01-26 |
2001-03-14 |
Astrazeneca Ab |
Process
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
CA2455963C
(en)
|
2001-07-31 |
2017-07-04 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Glp-1, exendin-4, peptide analogs and uses thereof
|
IL160983A0
(en)
|
2001-09-24 |
2004-08-31 |
Imp College Innovations Ltd |
Use of pyy for preparation of a medicament for modification of feeding behavior
|
US20040259952A1
(en)
|
2001-11-29 |
2004-12-23 |
Richat Abbas |
Formulations for oral administration of cromolyn sodium
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
KR100676025B1
(ko)
|
2002-02-01 |
2007-01-29 |
화이자 프로덕츠 인코포레이티드 |
아지쓰로마이신의 건조 과립화 제제
|
JP4417113B2
(ja)
|
2002-02-20 |
2010-02-17 |
エミスフェアー・テクノロジーズ・インク |
Glp−1分子の投与方法
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
WO2004066966A2
(en)
|
2003-01-17 |
2004-08-12 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Peptide yy analogs
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
US7557183B2
(en)
|
2003-03-19 |
2009-07-07 |
Eli Lilly And Company |
Polyethylene glycol linked GLP-1 compounds
|
AU2004241242A1
(en)
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
MXPA06000446A
(es)
|
2003-07-11 |
2006-04-07 |
Novartis Ag |
Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
|
WO2005014035A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk Health Care Ag |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
SI2932981T1
(sl)
|
2003-09-19 |
2021-11-30 |
Novo Nordisk A/S |
Albumin-vezavni derivati GLP-1
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
BRPI0417684A
(pt)
|
2003-12-18 |
2007-03-20 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
RU2006120079A
(ru)
|
2003-12-18 |
2008-01-27 |
Ново Нордиск А/С (DK) |
Производные глюкагоноподобного пептида-1 (glp-1)
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
AU2005211776B2
(en)
|
2004-02-11 |
2012-02-02 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
CN103897066A
(zh)
|
2004-02-11 |
2014-07-02 |
安米林药品有限责任公司 |
具有可选择特性的杂合多肽
|
AU2005224027B2
(en)
|
2004-03-17 |
2011-05-26 |
7Tm Pharma A/S |
Y2/Y4 selective receptor agonists for therapeutic interventions
|
EP2057996A3
(en)
|
2004-03-17 |
2009-11-04 |
7TM Pharma A/S |
Y4 selective receptor agonists for therapeutic intervention
|
CN100425282C
(zh)
|
2004-03-17 |
2008-10-15 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y2/y4选择性受体激动剂
|
WO2005089789A2
(en)
|
2004-03-17 |
2005-09-29 |
7Tm Pharma A/S |
Y2 selective receptor agonists for therapeutic interventions
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
EP1750729A2
(en)
|
2004-05-06 |
2007-02-14 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
AU2005240213B8
(en)
|
2004-05-06 |
2011-10-20 |
Emisphere Technologies, Inc. |
Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
|
EP1756039B1
(en)
*
|
2004-05-14 |
2012-10-17 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
EP1765408B1
(en)
|
2004-07-08 |
2015-12-09 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
CN105708787A
(zh)
|
2004-07-12 |
2016-06-29 |
爱密斯菲尔科技公司 |
用于递送肽yy和pyy激动剂的组合物
|
US7994119B2
(en)
|
2004-07-19 |
2011-08-09 |
University Of Cincinnati |
Compounds for control of appetite
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
WO2006084164A2
(en)
|
2005-02-01 |
2006-08-10 |
Emisphere Technologies, Inc. |
Gastric retention and controlled release delivery system
|
ES2438145T3
(es)
|
2005-02-02 |
2014-01-16 |
Novo Nordisk A/S |
Nuevos derivados de insulina
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
WO2006097536A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
AU2006224537A1
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
AU2006228525A1
(en)
|
2005-03-28 |
2006-10-05 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
JP2008542292A
(ja)
|
2005-05-26 |
2008-11-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
N末端修飾glp−1受容体モジュレーター
|
US20090054326A1
(en)
|
2005-07-11 |
2009-02-26 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
US8975227B2
(en)
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
CA2616583A1
(en)
|
2005-07-18 |
2007-01-25 |
Novo-Nordisk A/S |
Peptides for use in the treatment of obesity
|
CA2619426C
(en)
|
2005-08-19 |
2016-06-21 |
Amylin Pharmaceuticals, Inc. |
Exendin for treating diabetes and reducing body weight
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
JP2009508885A
(ja)
|
2005-09-21 |
2009-03-05 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy4選択性レセプターアゴニスト
|
JP2009508886A
(ja)
|
2005-09-21 |
2009-03-05 |
7ティーエム ファーマ エイ/エス |
治療的介入のためのy2選択性レセプターアゴニスト
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
JP2009515993A
(ja)
|
2005-11-17 |
2009-04-16 |
ノバルティス アクチエンゲゼルシャフト |
医薬組成物
|
NZ568772A
(en)
|
2005-12-07 |
2010-05-28 |
Hoffmann La Roche |
Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
|
JP2009520693A
(ja)
|
2005-12-08 |
2009-05-28 |
エムディーアールエヌエー,インコーポレイテッド |
安定化されたエキセンディン製剤の粘膜送達
|
JP2009519296A
(ja)
|
2005-12-14 |
2009-05-14 |
ノボ・ノルデイスク・エー/エス |
ポリペプチド延長タグ
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
EP2007397B1
(en)
|
2006-04-07 |
2013-07-24 |
Merrion Research III Limited |
Solid oral dosage form containing an enhancer
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
ES2395738T3
(es)
|
2006-05-09 |
2013-02-14 |
Novo Nordisk A/S |
Derivado de insulina
|
CA2654566A1
(en)
|
2006-06-09 |
2007-12-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
US9364502B2
(en)
|
2006-06-28 |
2016-06-14 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
BRPI0716539A2
(pt)
|
2006-09-07 |
2016-11-01 |
Emisphere Tech Inc |
métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
|
PE20121528A1
(es)
|
2006-09-13 |
2012-12-12 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
WO2008039351A2
(en)
|
2006-09-22 |
2008-04-03 |
Novartis Ag |
Method of manufacturing tablets containing pharmacologically active agents
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
JP2010516652A
(ja)
|
2007-01-18 |
2010-05-20 |
ノボ・ノルデイスク・エー/エス |
肥満の治療に使用される新規ペプチド
|
WO2008087190A2
(en)
|
2007-01-18 |
2008-07-24 |
Novo Nordisk A/S |
Use of peptides in combination with surgical intervention for the treatment of obesity
|
ATE507818T1
(de)
|
2007-03-02 |
2011-05-15 |
Novartis Ag |
Orale verabreichung eines calcitonins
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
US8835381B2
(en)
|
2007-06-12 |
2014-09-16 |
Glaxosmithkline Llc |
Methods for detecting protein in plasma
|
US8093689B2
(en)
*
|
2007-07-02 |
2012-01-10 |
Infineon Technologies Ag |
Attachment member for semiconductor sensor device
|
EP2322620A3
(en)
|
2007-07-09 |
2011-08-31 |
Imperial Innovations Ltd. |
Analogs of human pancreatic polypeptide and their effects on feeding behaviour
|
EP2182956A2
(en)
|
2007-08-29 |
2010-05-12 |
The Regents of the University of California |
Salicylanilide modified peptides for use as oral therapeutics
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
CN101868476B
(zh)
|
2007-09-05 |
2015-02-25 |
诺沃-诺迪斯克有限公司 |
胰高血糖素样肽-1衍生物及其制药用途
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
CA2699083A1
(en)
|
2007-09-11 |
2009-04-16 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
US8598314B2
(en)
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
US9241908B2
(en)
|
2007-10-16 |
2016-01-26 |
Biocon Limited |
Orally administrable solid pharmaceutical composition and a process thereof
|
MX2010004716A
(es)
|
2007-11-02 |
2010-12-17 |
Emisphere Tech Inc |
Metodo para tratar la deficiencia de vitamina b12.
|
US20090124639A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
CN102027007A
(zh)
|
2008-05-16 |
2011-04-20 |
诺沃-诺迪斯克有限公司 |
长效的y2和/或y4受体激动剂
|
JP5740689B2
(ja)
|
2008-08-18 |
2015-06-24 |
エンテラ バイオ エルティーディー. |
タンパク質の経口投与用の方法および組成物
|
JP5591243B2
(ja)
|
2008-09-12 |
2014-09-17 |
ノボ・ノルデイスク・エー/エス |
ペプチド又はタンパク質のアシル化の方法
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
ES2375832T3
(es)
|
2008-10-15 |
2012-03-06 |
Bayer Cropscience Ag |
Uso de ditiin-tetracarboximidas para combatir hongos titopatógenos.
|
MX2011004427A
(es)
|
2008-11-05 |
2011-05-31 |
Hoffmann La Roche |
Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
CN117547538A
(zh)
|
2009-02-13 |
2024-02-13 |
勃林格殷格翰国际有限公司 |
包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
|
WO2010096175A1
(en)
|
2009-02-20 |
2010-08-26 |
Ipsen Pharma S.A.S. |
Cytotoxic conjugates having neuropeptide y receptor binding compound
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
EP2477643A1
(en)
|
2009-09-18 |
2012-07-25 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
CN102596228A
(zh)
|
2009-10-13 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
神经肽-2受体(y-2r)激动剂
|
CN102905722A
(zh)
|
2009-11-13 |
2013-01-30 |
诺沃—诺迪斯克有限公司 |
长效y2受体激动剂
|
JP2013514976A
(ja)
|
2009-12-16 |
2013-05-02 |
ノッド ファーマシューティカルズ, インコーポレイテッド |
経口薬物送達のための組成物および方法
|
US20120329711A1
(en)
|
2009-12-16 |
2012-12-27 |
Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
US20110311621A1
(en)
|
2010-03-16 |
2011-12-22 |
Paul Salama |
Pharmaceutical compositions and methods of delvery
|
WO2011131646A1
(en)
|
2010-04-20 |
2011-10-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
WO2011136361A1
(ja)
|
2010-04-30 |
2011-11-03 |
株式会社 三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
PL3326620T3
(pl)
|
2010-12-16 |
2020-08-24 |
Novo Nordisk A/S |
Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
PL2696687T3
(pl)
|
2011-04-12 |
2017-06-30 |
Novo Nordisk A/S |
Pochodne podwójnie acylowanej GLP-1
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
CN111494323B
(zh)
|
2012-03-22 |
2023-03-28 |
诺和诺德股份有限公司 |
包含递送剂的组合物及其制备
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
WO2013178490A1
(en)
|
2012-05-29 |
2013-12-05 |
Novo Nordisk A/S |
Pancreatic polypeptide compounds and use
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
EP4406593A2
(en)
|
2012-07-01 |
2024-07-31 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
US20160067184A1
(en)
|
2013-05-02 |
2016-03-10 |
Novo Nordisk A/S |
Oral Dosing of GLP-1 Compounds
|
EP2992008B1
(en)
|
2013-05-02 |
2019-04-10 |
GlaxoSmithKline Intellectual Property Development Limited |
Therapeutic peptides
|
JP6629198B2
(ja)
|
2013-11-15 |
2020-01-15 |
ノヴォ ノルディスク アー/エス |
35位にβ−ホモアルギニン置換を有するHPYY(1−36)
|
US9085637B2
(en)
|
2013-11-15 |
2015-07-21 |
Novo Nordisk A/S |
Selective PYY compounds and uses thereof
|
WO2016128972A1
(en)
|
2015-02-09 |
2016-08-18 |
Entera Bio Ltd. |
Formulations for oral administration of active agents with controlled absorption profile
|
MX2017015105A
(es)
|
2015-06-12 |
2018-05-07 |
Novo Nordisk As |
Compuestos del peptido yy (pyy) selectivos y sus usos.
|
JP2018529749A
(ja)
|
2015-10-07 |
2018-10-11 |
シプルメット・ゲーエムベーハー |
ペプチド薬物を経口送達するための医薬製剤
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
SG11202006595RA
(en)
|
2018-02-02 |
2020-08-28 |
Novo Nordisk As |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|